Clinical Trials Browser

Uterine Cervical Neoplasms × balstilimab × 90 days × Clear all

NCT03894215 2026-03-27

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Phase 2 Terminated

Uterine Cervical Neoplasms